These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7557858)

  • 1. Utility of hepatitis C virus RNA determinations in hepatic tissue as an end point for interferon treatment of chronic hepatitis C.
    Gurakar A; Fagiuoli S; Faruki H; De Maria N; Balkan M; Van Thiel DH; Friedlander L
    Hepatology; 1995 Oct; 22(4 Pt 1):1109-12. PubMed ID: 7557858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic HCV-RNA as a predictor of outcome after interferon therapy in patients with chronic hepatitis C.
    Kondo M; Tanaka K; Ikeda M; Arata S; Saito S; Sakaguchi T; Morimoto M; Fujii T; Mitsui K; Okazaki H; Hoshino M; Sekihara H
    J Gastroenterol Hepatol; 1996 Mar; 11(3):236-40. PubMed ID: 8742919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.
    Shindo M; Arai K; Sokawa Y; Okuno T
    Ann Intern Med; 1995 Apr; 122(8):586-91. PubMed ID: 7887552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.
    Rostaing L; Izopet J; Baron E; Duffaut M; Puel J; Durand D
    Transplantation; 1995 May; 59(10):1426-31. PubMed ID: 7770930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant interferon-alfa therapy in children with chronic hepatitis C.
    Bortolotti F; Giacchino R; Vajro P; Barbera C; Crivellaro C; Alberti A; Nebbia G; Zancan L; De Moliner L; Bertolini A
    Hepatology; 1995 Dec; 22(6):1623-7. PubMed ID: 7489965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of hepatitis C virus RNA in liver tissue as a predictive marker of the response to interferon therapy in chronic hepatitis C.
    Hasui T; Shimomura H; Tsuji H; Wato M; Tsuji T
    Acta Med Okayama; 1994 Jun; 48(3):151-7. PubMed ID: 7524269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C.
    McGuinness PH; Bishop GA; Painter DM; Chan R; McCaughan GW
    Hepatology; 1996 Apr; 23(4):676-87. PubMed ID: 8666317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection.
    Davis GL; Lau JY
    J Hepatol; 1995; 22(1 Suppl):110-4. PubMed ID: 7602061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study.
    Sangiovanni A; Morales R; Spinzi G; Rumi M; Casiraghi A; Ceriani R; Colombo E; Fossati M; Prada A; Tavani E; Minoli G
    Hepatology; 1998 Mar; 27(3):853-6. PubMed ID: 9500717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.
    Orito E; Mizokami M; Nakano T; Terashima H; Nojiri O; Sakakibara K; Mizuno M; Ogino M; Nakamura M; Matsumoto Y
    J Med Virol; 1994 Dec; 44(4):410-4. PubMed ID: 7897373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
    J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.
    Kusaka S; Okusa T; Araki A; Fujiki K; Takashimizu I; Okayasu I; Yamamoto N; Sato C
    J Med Virol; 1995 Jul; 46(3):265-8. PubMed ID: 7561801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.